Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient. A case report.
Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient. A case report.
复制标题
癌症患者氟哌啶醇治疗期间的抗精神病药物恶性综合征。
DOI：
--
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Y. Uchitomi
中科院分区：
文献类型：
--
作者：
K. Tanaka;T. Akechi;M. Yamazaki;R. Hayashi;Y. Nishiwaki;Y. Uchitomi
本文报告一例64岁男性软腭癌患者发生神经阻滞剂恶性综合征。在氟哌啶醇治疗谵妄期间，患者出现意识障碍伴锥体外系体征。停用氟哌啶醇并以丹曲林和溴隐亭替代后，患者完全恢复。虽然主要的镇静剂被广泛用于临床肿瘤学来控制症状，但NMS在癌症患者中很少报告，可能是因为缺乏意识。NMS的早期识别和及时治疗可能会改善潜在的致命性结局。
A case of neuroleptic malignant syndrome (NMS) in a 64-year-old man with cancer of the soft palate is reported. During haloperidol treatment for delirium, the patient showed consciousness disturbance with extrapyramidal signs. With discontinuation of haloperidol and replacement by dantrolene and bromocriptine, the patient recovered completely. Although major tranquilizers are widely used in clinical oncology to manage symptoms, NMS has been rarely reported in cancer patients, presumably because of lack of awareness. Early recognition of NMS and prompt treatment may improve the potentially fatal outcome.